Format

Send to

Choose Destination
Eur J Immunol. 2018 Feb;48(2):355-365. doi: 10.1002/eji.201747128. Epub 2017 Nov 29.

KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition and enhances killing of tumor cells.

Author information

1
Innate Immunity Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
2
Division of Immunobiochemistry, Medical Faculty Mannheim, University Heidelberg, Germany.
3
Department of Immunology, Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Germany.

Abstract

To exploit autologous NK cells for cancer immunotherapy, it is highly relevant to circumvent killer cell immunoglobulin-like receptor (KIR)-mediated self-inhibition of human NK cells by HLA-I-expressing tumor cells. Here, we show that stimulation of NK cells with IL-12/15/18 for two days led to downregulation of surface expression of the inhibitory KIR2DL2/L3, KIR2DL1 and KIR3DL1 receptors on peripheral blood NK cells. Downregulation of KIR expression was attributed to decreased KIR mRNA levels which could be re-induced already 3 days after re-culture in IL-2. Reduced KIR2DL2/L3 expression on IL-12/15/18-activated NK cells resulted in less inhibition upon antibody-mediated KIR engagement and increased CD16-dependent cytotoxicity in redirected lysis assays. Most importantly, downregulated KIR2DL2/L3 expression enabled enhanced cytotoxicity of IL-12/15/18-stimulated NK cells against tumor cells expressing cognate HLA-I molecules. NK cells pre-activated with IL-12/15/18 were previously shown to exert potent anti-tumor activity and memory-like long-lived functionality, mediating remission in a subset of acute myeloid leukemia (AML) patients in a clinical trial. Our study reveals a novel mechanism of IL-12/15/18 in improving the cytotoxicity of NK cells by reducing their sensitivity to inhibition by self-HLA-I due to decreased KIR expression, highlighting the potency of IL-12/15/18-activated NK cells for anti-tumor immunotherapy protocols.

KEYWORDS:

Cancer immunotherapy; IL-12/15/18 activation; Killer cell immunoglobulin-like receptors (KIRs); NK cell receptors; NK cells

PMID:
29105756
DOI:
10.1002/eji.201747128
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center